This miRNA was poised to suppress vascular endothelial growth factor (VEGF) expression and EPC activities via targeting VEGF, indicating that the level of miR-361-5p in plasma from diseased individuals should be evaluated as a potential novel diagnostic biomarker for CAD. Here, VEGFA is linked to coronary artery disorder.